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MaClassically, the 3 pillars of atrial ﬁbrillation (AF) management have included anticoagulation for prevention of throm-
boembolism, rhythm control, and rate control. In both prevention and management of AF, a growing body of evidence
supports an increased role for comprehensive cardiac risk factor modiﬁcation (RFM), herein deﬁned as management of
traditional modiﬁable cardiac risk factors, weight loss, and exercise. In this narrative review, we summarize the evidence
demonstrating the importance of each facet of RFM in AF prevention and therapy. Additionally, we review emerging data
on the importance of weight loss and cardiovascular exercise in prevention and management of AF. (J Am Coll Cardiol
2015;66:2899–906) © 2015 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) is the most commonsustained arrhythmia and represents arapidly growing epidemic (1). It is projected
that the prevalence will rise from 5.2 million in
2010 to 12.1 million in 2030, driven primarily by
our aging population (2). AF is associated with
increased morbidity, mortality, and rising health
care–associated expenses (3,4).
Unsurprisingly, many modiﬁable risk factors
associated with atherosclerotic cardiovascular dis-
ease (ASCVD) have also been associated with AF
(Central Illustration). Although the most recent AF
practice guidelines acknowledge these risk factors,
they provide no evidence-based recommendations
on diet, exercise, and lifestyle changes in AF pri-
mary and secondary prevention (5). In 2013, the
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as a key research focus (6). Of note, there are
numerous other risk factors for AF, such as valvular
heart disease, thyroid disease, or chronic obstruc-
tive pulmonary disease, which are not thought of as
classical risk factors for atherosclerotic heart dis-
ease. Such conditions also have known causal
relationships with AF and also have implications for
management strategies. These other AF risk factors
warrant investigation in the work-up of new di-
agnoses of AF.
OBESITY AND WEIGHT LOSS
The rise in prevalence of obesity has been well
documented, particularly in the United States, where
an estimated one-third of adults are obese (7). Duringiversity School of Medicine, Baltimore, Maryland. Dr.
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2900the past 5 years, a number of studies have
established that obesity is closely linked to
AF risk. Body mass index (BMI) is part of
prediction models for new-onset AF (8). The
connection between obesity and AF has been
shown to occur independently of the many
comorbidities associated with obesity (9,10).
In the ARIC (Atherosclerosis Risk In Com-
munities) study (N ¼ 14,598), 17% of AF risk
was attributed to obesity or overweight sta-
tus (11). In the WHS (Women’s Health Study)
(N ¼ 34,309), for every 1 kg/m2 increase inBMI, the relative AF risk increased by 5% (10). In the
Women’s Health Initiative cohort of 93,676 females,
for every 1 kg/m2 increase in BMI, AF relative risk
increased by 12%. (12). Interestingly, higher levels of
physical activity attenuated the AF risk conferred by
obesity (13). BMI >35 kg/m2 was also associated with
increased AF risk by a hazard ratio of 3.50 in young,
healthy women (14).
In a recent meta-analysis of 51 studies and 626,603
patients, for every 5 kg/m2 increase in BMI, there was
a 10% to 29% higher relative risk for new-onset or
post-operative AF (15). In a subanalysis of 16 studies
and 5,864 patients undergoing AF ablation, the risk of
AF recurrence increased by 13% for every 5 kg/m2
increase in BMI (15). Adiposity measures other than
BMI have also been associated with increased AF
risk. In a Danish registry of 55,273 participants and
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tribute to the development and consequences of atrial ﬁbrillation (
F ¼ risk factor; RFM ¼ risk factor modiﬁcation.13.5 years of follow-up, increased total body fat
mass assessed by bioelectrical impendence was
associated with higher incidence of AF (16).
Several mechanisms underlie the association
between obesity and AF. In a sheep model fed a high-
caloric diet, obesity was associated with left atrial
enlargement and ﬁbrosis, atrial inﬂammatory, and
lipid inﬁltration, as well as changes in atrial elec-
trophysiological properties, ultimately leading to
increased rates of spontaneous and induced AF (17). In
an ovine model of obesity sustained for 8 months,
obesity was associatedwith inﬁltration of the left atrial
posterior myocardium by epicardial fat and reduced
endocardial voltage, representing a potential substrate
for AF (18).
In humans, increased BMI has been associated
with increased left atrial size (19), which, in turn, is
associated with higher AF risk (20). Increased peri-
cardial fat volume has also been described in obese
individuals and is related to the presence, severity,
and post-ablation recurrence of AF, independent of
BMI, suggesting a local pathogenic effect of pericar-
dial fat (21). Obesity has also been associated with
increased epicardial fat thickness, which may lead to
altered atrial electrophysiology and sympathovagal
imbalance of the atria (22–24). Clinically, epicardial
fat has been associated with AF (25). Lastly, obesity is
a state of chronic, low-grade, systemic inﬂammation
(26). Systemic inﬂammation has a key role inolic RFs and AF
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2901initiation and perpetuation of AF and may contribute
to the association of obesity with AF (27).
Recent clinical trials demonstrate that weight
reduction, in the context of a comprehensive risk
factor modiﬁcation (RFM) plan, has an important role
in AF management (Table 1). In a single-center ran-
domized trial, 150 overweight patients with symp-
tomatic AF were randomized to weight management
versus lifestyle advice, in addition to standard ther-
apy for AF (28). The weight management consisted of
a prescribed exercise routine and a low-calorie diet,
with improvement in BMI from 32.8 to 27.2 kg/m2 at
15 months versus no change for the control group. At
15 months, the weight management group had
reduced frequency of AF episodes, reduced duration
in AF, and lower symptom severity scores.
The LEGACY-AF (Long-Term Effect of Goal
Directed Weight Management on Atrial Fibrillation
Cohort: A 5 Year Follow-Up Study) study investigated
the impact of RFM and weight loss in longer-term AF
management (30). Patients with a BMI $27 kg/m2 and
AF (N ¼ 825) were offered weight management and
standard therapy for AF at the discretion of the
treating physician. At 5-year follow-up, a dose–
response relationship was seen, with greater weight
loss resulting in reduced AF burden and symptoms.
Weight loss $10% was associated with >6-fold
decrease in arrhythmia-free survival. Fluctuations of
weight >5% within the study time period offset some,
but not all, of the beneﬁts of weight loss.
Weight loss has also been demonstrated to reduce
AF recurrence after ablation procedures. In the
ARREST-AF (Aggressive Risk Factor Reduction Study
for Atrial Fibrillation and Implications for the Outcome
of Ablation), patients with AF and obesity undergoing
catheter ablation were offered the chance to partici-
pate in a group in a nonrandomized fashion (29). At a
mean follow-up of 42 months after catheter ablation,
patients in the RFMgroup had signiﬁcant reductions in
weight, blood pressure, and lipid proﬁle, and improved
glycemic control. There was a signiﬁcant decrease in
AF frequency, duration, symptoms, and arrhythmia-
free survival with the RFM group. Additionally, obese
patients have been observed to receive at least a 2-fold
higher effective radiation dose compared with
nonobese patients during an AF ablation (33).
The epidemiological link between obesity and AF is
clear, and there is increasing understanding of the
pathophysiology linking the 2 conditions. Recent data
support the importance of weight loss in AF man-
agement. Of note, weight loss did not occur in isola-
tion in the studies discussed earlier, but rather
included components of exercise, diet, and modiﬁ-
cation of other risk factors. The link between weightloss and AF therapy is likely multifactorial, because
routine RFM and weight-loss counseling result in
improvement in other comorbid conditions that are
also independently associated with AF. However,
weight loss does result in atrial structural changes,
supporting a direct link between weight loss and
improved AF outcomes (34). Currently, the body of
evidence is enough to strongly recommend weight
loss for both prevention and management of AF.
EXERCISE AND FITNESS
The beneﬁts of routine exercise in improving ASCVD
risk factors have been well established, and guide-
lines recommend regular brisk exercise for this
purpose (35). Observational studies have shown
increased risk of AF in young athletes or in those
performing endurance training (36,37). A common
theme in these studies is involvement in regular long-
duration endurance training that is well beyond the
scope of what would be practiced by the typical pa-
tient with AF and other comorbidities.
In the Cardiovascular Health Study, the incidence
of AF was lower in individuals performing light-
to-moderate exercise compared with those per-
forming no exercise (38). There was no difference in
AF incidence between individuals performing high-
intensity exercise versus no exercise. Among those
who walked for exercise, walking greater distances
or at a faster pace was associated with a greater
reduction in incident AF. In the Women’s Health
Initiative study, increased physical activity was
associated with less incident AF and appeared to
mediate some of the relationship between obesity
and AF (13). Two meta-analyses examining the
relationship of routine nonendurance exercise and
AF reported no association between exercise and AF
risk (39,40).
In a cohort of 64,561 adults with a mean follow-up
of 5.4 years, for each 1 metabolic equivalent (MET)
achieved during treadmill stress testing, there was a
7% decreased relative risk for AF development (41). In
the recent CARDIO-FIT (Impact of CARDIOrespiratory
FITness on Arrhythmia Recurrence in Obese In-
dividuals with Atrial Fibrillation) study, 308 obese
(BMI $27 kg/m2) patients with AF were enrolled in a
tailored exercise program. Patients that had high
cardiorespiratory ﬁtness had greater arrhythmia-free
survival with and without rhythm-control strategies.
Patients who improved their ﬁtness level by $2 METs
had a 2-fold higher probability of AF-free survival, as
well as lower AF burden and symptom severity
compared with those that improved their ﬁtness
by <2 METs (32).
TABLE 1 Interventional Studies Assessing the Effect of RFM on AF Outcomes
First Author
(Ref. #) Year Design Patient Population Sample Size Intervention Comparison Follow-up
Results (Intervention vs.
Control Group)
Obesity
Abed et al. (28) 2013 Single-center,
partially blinded,
RCT (weight-loss
counselors were
not blinded)
Overweight and
obese ambulatory
patients with
symptomatic AF
150
(I ¼ 75;
C ¼ 75)
Weight management General lifestyle
advice
15 months  Greater weight loss (14.3 vs. 3.6 kg)
 Reduced AF burden and severity scores
(11.8 vs. 2.6 points and 8.4 and 1.7 points,
respectively)
 Less frequent AF episodes
 Reduced cumulative AF duration (692 min
reduction vs. 419 min increase)
 Reduced IVS and LAA
Pathak et al. (29) 2014 Single-center,
nonrandomized,
placebo-
controlled
trial
Consecutive patients
with BMI $27 kg/m2 and $1 RF
(HTN, glucose intolerance/DM,
HLD, OSA, smoking, or alcohol
excess) undergoing initial catheter
ablation for symptomatic AF,
despite the use of antiarrhythmic
medication
149
(I ¼ 61;
C ¼ 88)
RFM by a physician-led
clinic (HTN control,
weight management,
lipid management,
glycemic control, OSA
management,
smoking and alcohol
counseling)
Information on
RFM was
provided
42 months  Greater reductions inweight andbloodpressure,
as well as improved glycemic control and lipid
proﬁle.
 Decreased AF frequency, duration, symp-
toms, and symptom severity.
 Improved arrhythmia-free survival after a
single or multiple procedures (with or
without the use of anti-arrhythmic agents)
Pathak et al. (30) 2015 Single-center,
single-arm,
study
Consecutive patients with
symptomatic paroxysmal or
persistent AF and BMI $27 kg/m2
355 Weight management No control arm 46–48 months  Decreased AF burden and symptom severity
in patients that lost $10% of their weight
compared to those that lost <10%
 Weight loss $10% was associated with a
6-fold greater probability of arrhythmia-
free survival
 Fluctuations of weight >5% offset some,
but not all, beneﬁts of weight loss
Diabetes
Fatemi et al. (31) 2014 Multicentric,
RCT
Patients with CVD or aged 55 to 79 yrs
and had anatomic evidence of
signiﬁcant ASCVD, albuminuria,
LVH, or $2 additional RFs (HLD,
HTN, current smoking status, or
obesity)
10,251
(I ¼ 5,040;
C ¼ 5,042)
Intensive glucose
control
(HbA1c <6.0%)
Standard
strategy
(HbA1c:
7.0%–7.9%)
4.7 yrs  There was no difference in AF incidence
between the 2 groups
 Patients with DM and new-onset AF had a
hazard ratio of 2.65 for all-cause mortality
Exercise and cardiorespiratory ﬁtness
Pathak et al. (32) 2015 Single-center,
single-arm
study
Consecutive patients with
symptomatic paroxysmal or
persistent AF and BMI $27 kg/m2
308 Weight and risk
factor management
program, structured
exercise program
No control arm 49 months  Greatest arrhythmia-free survival (with and
without rhythm control strategies) was
observed in patients with high
cardiorespiratory ﬁtness compared with
adequate or low cardiorespiratory ﬁtness
 Decreased AF burden and symptom severity
in patients with cardiorespiratory ﬁtness
gain $2 METs, compared with <2 METs
 2-fold greater probability of arrhythmia-
free survival in patients with
cardiorespiratory ﬁtness gain $2 METs,
compared with <2 METs
AF¼ atrial ﬁbrillation; ASCVD ¼ atherosclerotic cardiovascular disease; BMI¼ body mass index; C ¼ sample size of the control group; CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; HLD¼ hyperlipidemia; HTN¼ hypertension; I¼ sample size of the intervention
group; IVS ¼ intraventricular septum thickness; LAA ¼ left atrial area; LVH ¼ left ventricular hypertrophy; METs ¼ metabolic equivalents; OSA ¼ obstructive sleep apnea; RCT ¼ randomized controlled trial; RF ¼ risk factors; RFM ¼ risk factor management.
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2903Although there is a link between endurance exer-
cise and AF, this represents a small fraction of
patients and a subgroup of people already at low risk
of developing AF. There are no data to suggest that
routine light or moderate exercise puts patients at
increased risk of AF, and there is evidence that
light-to-moderate exercise may decrease incident AF.
In addition, increased ﬁtness is associated with
reduced AF risk. Given the other cardiovascular
beneﬁts of routine exercise, it is logical to recom-
mend regular, moderate exercise as part of routine AF
prevention and management.
HYPERTENSION
Elevated blood pressure has consistently been one the
strongest predictors of the development of AF (42).
Even high-normal blood pressure has been linked with
increased risk of AF (43). The increased afterload leads
to both atrial and ventricular structural remodeling,
resulting in diastolic dysfunction and left atrial
enlargement and ﬁbrosis (44,45). These changes in
turn lead to increased AF (45).
AF risk reduction via blood pressure control has
not been consistently shown. Therefore, control of
hypertension (HTN) in those without cardiovascular
disease is not currently recommended for prevention
of AF (5). However, HTN plays an important role in
the management of AF in regard to thromboembolic
risk. The presence of HTN is a risk factor for stroke in
patients with AF in both the CHADS2 and CHADS2-
VASc risk stratiﬁcation instruments (46). Control of
HTN with losartan has been associated with a 2-fold
reduction of stroke rates (47).
It is well-documented that HTN is associated with
increased risk of AF and increased risk of complica-
tions of AF, particularly stroke. Although treatment of
HTN has not been consistently shown to decrease AF
risk, it is an important component of reducing throm-
boembolic risk and of any AF management strategy.
CHOLESTEROL
Studies assessing associations between dyslipidemia
and incident AF report variable results. Multiple
studies have shown that low levels of high-density
lipoprotein cholesterol (<35 mg/dl) are associated
with increased risk of new-onset AF (48,49). How-
ever, other studies have found no association
between high-density lipoprotein cholesterol and
incident AF, and increased total cholesterol and low-
density lipoprotein cholesterol have been associated
with a lower incidence of AF (50,51).
A number of studies have evaluated the roles of
statins and ﬁsh oil in AF prevention. In ameta-analysisof 6 randomized controlled trials involving 3,557 pa-
tients, statin therapy decreased the relative risk of
incident or recurrent AF by 61% compared with stan-
dard of care (52). In a subgroup analysis, the beneﬁt
from statin use was limited to those with a previous
history of AF and those undergoing cardiac surgery or
treatment for ACS.
Prospective data on the role of ﬁsh oil in decreasing
the incidence of AF are limited. Two randomized,
double-blind, placebo-controlled trials of high-dose
omega-3 (4 to 8 g/day) failed to show a reduction
in AF recurrence among patients with a history
of paroxysmal or persistent AF (53,54). In meta-
analyses, ﬁsh oil supplementation was not associ-
ated with reduction of AF risk (55).
Statins are, however, associated with decreased risk
of post-operative AF. A meta-analysis of randomized
controlled and observational studies in cardiac surgery
including 17,643 patients demonstrated less post-
operative AF with pre-operative statin use (56).
In total, the data linking abnormal lipid proﬁles
and incident AF has been mixed, as have been studies
of statins and ﬁsh oils in prevention of AF. On the
basis of the evidence, recommendations for use of
lipid-lowering agents for the purpose of preventing or
managing AF is limited to its role in cardiac surgery
patients.
DIABETES
Diabetes is an independent risk factor for AF (57,58).
This has been corroborated with long-term prospec-
tive population cohort studies. In the Framingham
Heart Study, diabetes was associated with 40% higher
risk of AF in men and 60% higher risk in women after
38 years of follow-up (59).
Regarding mechanisms underlying the association
of diabetes and AF, cardiac autonomic neuropathy
has been implicated by leading to sympathetic over-
activity and neural remodeling (60,61). Dysfunctional
cardiac autonomic activity can trigger AF, especially
with changes in vagal tone (62).
There are limited data on diabetes management and
AF risk. The Action to Control Cardiovascular Risk in
Diabetes study randomized 10,251 patients to intense
glycemic control (HbA1c <6.0%) or a standard target
(7.0% to 7.9%). There was no difference in new-onset
AF between the 2 arms (31). In a prospective study of
263 consecutive patients undergoing ﬁrst-time cath-
eter ablation for AF, there was no difference in AF
recurrence between those patients with and without
diabetes; however, there was a signiﬁcant increase in
procedural complications including stroke, cardiac
tamponade, and hematomas among those with
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2904diabetes (63). Other studies have shown a greater atrial
tachyarrhythmia recurrence rate following catheter
ablation for AF in patients with diabetes (64,65).
In summary, there is currently insufﬁcient evi-
dence to suggest that any particular management
strategy for diabetes directly affects the risk of
developing AF. However, it is reasonable to hypoth-
esize that optimal management of diabetes and
prevention of cardiovascular complications may
indirectly reduce risk of AF.
OBSTRUCTIVE SLEEP APNEA
Obstructive sleep apnea (OSA) is highly prevalent in
patients with AF. In a prospective analysis, approxi-
mately 50% of AF patients had OSA, as compared with
32% of controls (66). After a multivariate analysis
looking at traditional risk factors for OSA, AF had
a greater association with OSA than BMI, HTN, or
diabetes.
Mechanisms by which OSA contributes to AF
risk include intermittent nocturnal hypoxemia/
hypercapnia, surges in sympathetic tone and blood
pressure during apneic episodes, and increased
inﬂammation (67,68). All of these factors may
contribute to left atrial remodeling and chamber dila-
tion, contributing to perpetuation of AF.
Rates of AF recurrence after electrical cardioversion
arehigher inpatientswithOSAwhoarenot treatedwith
nocturnal positive-pressure therapy. In a prospective
study of patients with OSA referred for electrical car-
dioversion (N ¼ 39), the 12-month AF recurrence rate
was 82% in patients who were not appropriately
receiving positive-pressure therapy versus 42% in pa-
tients using appropriate OSA treatment (69).
In a prospective study of AF patients with OSA
referred for index pulmonary vein isolation (PVI)
procedure, arrhythmia-free survival at 1 year was
higher in those who were compliant with positive-
pressure therapy (71.9%) compared with patients
who were not (36.7%) (70). Arrhythmia-free survival
after PVI in treated OSA patients was similar to
arrhythmia-free survival in patients who did not
have OSA. The risk of AF recurrence after PVI in
untreated OSA patients was the same as the risk of
recurrence in OSA patients with AF who were medi-
cally managed without PVI.There is clear evidence demonstrating OSA to be a
signiﬁcant risk factor for AF. In addition, treatment of
OSA is an important component of AF management,
particularly when cardioversion or PVI is used. The
strength of the evidence warrants consideration of
routine clinical screening for OSA prior to use of a
rhythm control strategy.
TOBACCO AND ALCOHOL
Studies yield conﬂicting results in regard to the
association of tobacco use and incident AF (71–73).
Alcohol consumption has been associated with
an increased risk of developing AF in a dose-
dependent manner (74). Although tobacco and
alcohol have been associated with increased risk of
AF, the effect of tobacco cessation or reduction in
alcohol intake on management of AF is less clear.
They are, therefore, components of a comprehen-
sive strategy to lower AF risk, but cannot be rec-
ommended speciﬁcally for the purpose of improving
AF outcomes.
CONCLUSIONS
In addition to anticoagulation, rhythm control, and
rate control, a fourth pillar of AF management is
emerging. There is growing evidence supporting
aggressive RFM, especially weight loss, in the
context of a comprehensive RFM plan. These bene-
ﬁts are seen in AF prevention, success rates in AF
management, and in reducing complications of AF,
including stroke. Although fundamental in primary
care and cardiology for the management of ASCVD,
RFM in AF deserves similar recognition. The current
body of evidence supports a comprehensive strategy
of weight loss, exercise, and ﬁtness, screening for
OSA, and treatment of traditional modiﬁable ASCVD
risk factors. Further research needs to be performed
before making speciﬁc recommendations and
guidelines on appropriate weight loss and ﬁtness
targets.
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